A Phase 1 interventional study of Placebo and Tezepelumab in Healthy Volunteers, sponsored by Amgen. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-21.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective is to evaluate the safety, tolerability, and immunogenicity of multiple-dose administration of tezepelumab in healthy adults.
This study will follow a randomized, multiple-dose, double-blind, placebo-controlled, sequential dose-escalation study design. The study will consist of five subcutaneous (SC) cohorts and one intravenous (IV) cohort. Each dose cohort is planned to enroll 8 participants, randomized such that 6 participants will receive tezepelumab and 2 will receive placebo (3:1 ratio).
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tezepelumab will be administered subcutaneously (SC) at doses from 35 mg once every 28 days (Q28D) (cohort 1) up to 210 mg once every 7 days (Q7D) (cohort 5) and an intravenous (IV) dose cohort of 700 mg Q28D (cohort 6).
Drug: Tezepelumab
Two participants in each cohort (cohorts 1 to 6) will receive matching placebo administered subcutaneously (cohorts 1-5) or intravenously (cohort 6), matching the treatment regiment of tezepelumab.
Drug: Placebo
Administered by subcutaneous or intravenous injection.
Administered by subcutaneous or intravenous injection
Also known as: AMG 157, Tezspire
Number of Participants With Treatment-emergent Adverse Events
Adverse events (AEs) include any untoward medical occurrence in a trial participant administered a study drug and does not necessarily have a causal relationship with this treatment. AEs include worsening of a pre-existing medical condition and laboratory value changes requiring therapy or adjustment in prior therapy. AEs were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 3, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = severe AE, Grade 4 = life-threatening AE and Grade 5 = death due to AE. Relationship to study treatment was determined by the investigator. A serious adverse event (SAE) is defined as an AE that met 1 or more of below criteria: * was fatal; * was life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * was a congenital anomaly/birth defect; * other significant medical hazard.
Time frame: From first dose of study drug up to day 169
Number of Participants Who Developed Anti-tezepelumab Antibodies After Initiation of Treatment
All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab. The number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.
Time frame: For Q28D groups: Days 28, 56, 85, 113, and 169; For Q14D and Q7D groups: Days 29, 57, 85, 113, 141, and 169
Time of Maximum Observed Concentration (Tmax) of Tezepelumab
The pharmacokinetic (PK) parameter Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/ml.
Time frame: First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose
Maximum Observed Concentration (Cmax) of Tezepelumab
The PK parameter Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/ml.
Time frame: First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose
Area Under the Concentration-time Curve Over the Dosing Interval (AUCtau) for Tezepelumab
The PK parameter AUCtau was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The dosing interval (tau) was 28 days, 14 days or 7 days depending on the treatment arm. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/ml.
Time frame: First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose
Accumulation Ratio Based on AUCtau
Accumulation ratio (AR) based on AUCtau was calculated as AUCtau after last dose / AUCtau after first dose, except for the Q7D cohort where AR was calculated as AUCtau after last dose / area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) after first dose.
Time frame: First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose
Accumulation Ratio Based on Cmax
Accumulation ratio based on Cmax calculated as Cmax after last dose / Cmax after first dose
Time frame: First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose
This study was conducted at a single center in the United States.
| Milestone | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV | Placebo |
|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 7 | 6 | 12 |
| Completed | 5 | 3 | 5 | 5 | 5 | 3 | 8 |
| Not completed | 1 | 3 | 1 | 1 | 2 | 3 | 4 |
| Withdrew: Noncompliance | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Administrative decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 3 | 1 |
Adverse events (AEs) include any untoward medical occurrence in a trial participant administered a study drug and does not necessarily have a causal relationship with this treatment. AEs include worsening of a pre-existing medical condition and laboratory value changes requiring therapy or adjustment in prior therapy. AEs were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 3, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = severe AE, Grade 4 = life-threatening AE and Grade 5 = death due to AE. Relationship to study treatment was determined by the investigator. A serious adverse event (SAE) is defined as an AE that met 1 or more of below criteria: * was fatal; * was life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * was a congenital anomaly/birth defect; * other significant medical hazard.
| Participants | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV | Placebo |
|---|---|---|---|---|---|---|---|
| Any adverse event | 4 | 4 | 2 | 6 | 5 | 3 | 10 |
| Serious adverse events | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| AE Leading to discontinuation of study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AE Leading to discontinuation from study | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 adverse events | 1 | 0 | 0 | 1 | 1 | 1 | 2 |
| Grade 4 adverse events | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Fatal (grade 5) adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any treatment-related adverse event | 2 | 0 | 1 | 1 | 3 | 0 | 2 |
The pharmacokinetic (PK) parameter Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/ml.
| hours | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV |
|---|---|---|---|---|---|---|
| First dose | 160 (69.7 to 167) | 71.5 (70.4 to 167) | 118 (68.7 to 166) | 70.7 (69.9 to 168) | 164 (66.9 to 165) | 4.00 (1.13 to 4.17) |
| Last dose | 166 (68.6 to 176) | 71.8 (70.7 to 167) | 167 (69.3 to 168) | 66.5 (65.1 to 162) | 74.4 (65.9 to 164) | 3.97 (1.17 to 4.03) |
All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab. The number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.
| Participants | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV | Placebo |
|---|---|---|---|---|---|---|---|
| Anti-tezepelumab binding antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anti-tezepelumab neutralizing antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The PK parameter Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/ml.
| µg/mL | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV |
|---|---|---|---|---|---|---|
| First dose | 3.70 ± 1.16 | 10.7 ± 3.13 | 23.6 ± 9.50 | 23.8 ± 5.40 | 18.0 ± 4.58 | 294 ± 48.2 |
| Last dose | 6.29 ± 2.02 | 16.6 ± 2.02 | 37.4 ± 17.5 | 63.8 ± 13.5 | 117 ± 45.6 | 370 ± 74.9 |
The PK parameter AUCtau was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The dosing interval (tau) was 28 days, 14 days or 7 days depending on the treatment arm. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/ml.
| days*µg/mL | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV |
|---|---|---|---|---|---|---|
| First dose | 78.9 ± 23.4 | 237 ± 50.5 | 481 ± 171 | 263 ± 49.2 | 84.3 ± 34.9 | 2980 ± 395 |
| Last dose | 136 ± 35.9 | 333 ± 28.8 | 799 ± 338 | 787 ± 180 | 732 ± 224 | 4050 ± 1270 |
Accumulation ratio (AR) based on AUCtau was calculated as AUCtau after last dose / AUCtau after first dose, except for the Q7D cohort where AR was calculated as AUCtau after last dose / area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) after first dose.
| ratio | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV |
|---|---|---|---|---|---|---|
| Accumulation Ratio Based on AUCtau | 1.82 ± 0.262 | 1.64 ± 0.0883 | 1.59 ± 0.242 | 2.89 ± 0.892 | 8.23 ± 1.93 | 1.34 ± 0.314 |
Accumulation ratio based on Cmax calculated as Cmax after last dose / Cmax after first dose
| ratio | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV |
|---|---|---|---|---|---|---|
| Accumulation Ratio Based on Cmax | 1.79 ± 0.392 | 1.66 ± 0.0901 | 1.59 ± 0.288 | 2.84 ± 0.965 | 6.74 ± 1.69 | 1.30 ± 0.176 |
Collected over From first dose of study drug up to day 169. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tezepelumab 35 mg Q28D | — | 1/6 (16.7%) | 4/6 (66.7%) |
| Tezepelumab 105 mg Q28D | — | 0/6 (0%) | 4/6 (66.7%) |
| Tezepelumab 210 mg Q28D | — | 0/6 (0%) | 2/6 (33.3%) |
| Tezepelumab 210 mg Q14D | — | 0/6 (0%) | 6/6 (100%) |
| Tezepelumab 210 mg Q7D | — | 0/7 (0%) | 5/7 (71.4%) |
| Tezepelumab 700 mg Q28D IV | — | 0/6 (0%) | 3/6 (50%) |
| Tezepelumab Total | — | 1/37 (2.7%) | 24/37 (64.9%) |
| Placebo | — | 0/12 (0%) | 10/12 (83.3%) |
| Event | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV | Tezepelumab Total | Placebo |
|---|---|---|---|---|---|---|---|---|
| Hepatitis CInfections and infestations | 1/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 1/37 | 0/12 |
| Event | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV | Tezepelumab Total | Placebo |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/6 | 2/6 | 1/6 | 2/6 | 3/7 | 0/6 | 8/37 | 2/12 |
| PruritusSkin and subcutaneous tissue disorders | 2/6 | 0/6 | 0/6 | 0/6 | 1/7 | 0/6 | 3/37 | 0/12 |
| Injection site haematomaGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 2/7 | 0/6 | 2/37 | 1/12 |
| Injection site painGeneral disorders | 0/6 | 0/6 | 1/6 | 0/6 | 2/7 | 0/6 | 3/37 | 0/12 |
| Blood creatine phosphokinase increasedInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 2/7 | 1/6 | 3/37 | 2/12 |
| Eye irritationEye disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/7 | 0/6 | 1/37 | 0/12 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/7 | 0/6 | 1/37 | 0/12 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 1/7 | 0/6 | 2/37 | 0/12 |
| Application site dermatitisGeneral disorders | 0/6 | 1/6 | 0/6 | 1/6 | 0/7 | 0/6 | 2/37 | 0/12 |
| FatigueGeneral disorders | 0/6 | 0/6 | 0/6 | 1/6 | 1/7 | 0/6 | 2/37 | 1/12 |
Participants who received at least 1 dose of study drug (Safety population).
| Age, Continuous(year) | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 29.8 ± 9.3 | 34.8 ± 5.8 | 32.3 ± 5.3 | 31.5 ± 5.6 | 36.1 ± 7.7 | 27.7 ± 4.1 | 34.1 ± 5.2 | 32.6 ± 6.4 |
| Sex: Female, Male(Participants) | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 4 | 1 | 0 | 2 | 7 |
| Male | 6 | 6 | 6 | 2 | 6 | 6 | 10 | 42 |
| Race/Ethnicity, Customized(Participants) | Tezepelumab 35 mg Q28D | Tezepelumab 105 mg Q28D | Tezepelumab 210 mg Q28D | Tezepelumab 210 mg Q14D | Tezepelumab 210 mg Q7D | Tezepelumab 700 mg Q28D IV | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| White | 3 | 0 | 2 | 1 | 4 | 3 | 4 | 17 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 |
| Hispanic or Latino | 3 | 6 | 4 | 5 | 3 | 1 | 7 | 29 |
No study locations are listed for this record.
Ran from Sep 2009 to primary completion in Jan 2011, 15 months.
Results were first posted in May 2022, 11 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab